Teva, IRS Resolve $44M Case Over Patent Defense Costs
Teva Pharmaceuticals and the IRS resolved a $44.3 million dispute Tuesday that stemmed mostly from disallowed patent defense costs, agreeing that Teva had a $15.9 million overpayment for 2009 and had...To view the full article, register now.
Already a subscriber? Click here to view full article